Relapse after conservative surgery combined with triptorelin acetate versus conservative surgery only in women with focal adenomyosis: study protocol for a multicenter, prospective, randomized controlled trial
Open Access
- 28 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 21 (1), 1-7
- https://doi.org/10.1186/s13063-020-04294-2
Abstract
The preservation of fertility and integrity of the reproductive organs has increasingly been of concern to most women with adenomyosis. Adenomyomectomy is conservative surgery that is now widely applied; however, relapse is a serious problem after the operation. Postoperative treatment, such as gonadotropin-releasing hormone agonist (GnRHa) has been suggested to result in reducing the rate of disease recurrence. However, there is still a lack of evidence from randomized clinical trials examining the efficacy of GnRHa in decreasing the postoperative recurrence rate. Relapse after conservative surgery combined with triptorelin acetate versus conservative surgery only in women with focal adenomyosis is a multicenter, prospective, randomized controlled trial. The primary outcome is relapse assessed using a visual analogue scale (VRS) and numeric rating scale (NRS), pictorial blood loss assessment chart (PBAC) score, and the size of the uterus and the lesion as measured by two/three-dimensional color doppler ultrasonography (2D/3D-CDUS) or magnetic resonance imaging (MRI). The secondary outcomes include quality of life, clinical pregnancy, ovarian reserve, adverse events, assessment by the Short Form (36) Health Survey and Female Sexual Function index, serum follicle-stimulating hormone, estradiol levels, and anti-Muellerian hormone and so on. All these indexes are measured at 3, 6, 12, 18, 24, 30, and 36 months after conservative surgery. The result of this large, multicenter randomized trial will provide evidence for one of the strategies of long-term management in focal adenomyosis after conservative operation. Chinese Clinical Trial Registry: ChiCTR1800014340. Registered on 6 January 2018.Other Versions
This publication has 19 references indexed in Scilit:
- Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?Human Reproduction Update, 2018
- Uterine adenomyosis and adenomyoma: the surgical approachFertility and Sterility, 2018
- Abnormal uterine bleedingBritish Medical Bulletin, 2017
- Conservative surgical treatment of adenomyosis to improve fertility: Controversial values, indications, complications, and pregnancy outcomesTaiwanese Journal of Obstetrics & Gynecology, 2015
- Long-term follow-up of severely symptomatic women with adenomyoma treated with combination therapyTaiwanese Journal of Obstetrics & Gynecology, 2013
- Surgical procedure to conserve the uterus for future pregnancy in patients suffering from massive adenomyosisReproductive BioMedicine Online, 2011
- Comparison of surgery alone and combined surgical-medical treatment in the management of symptomatic uterine adenomyomaFertility and Sterility, 2008
- Uterine myoma: a condition amendable to medical therapy?Emerging Drugs, 2008
- Add-back therapy in the treatment of endometriosis-associated painFertility and Sterility, 2004
- Surgical and medical treatment of adenomyosisHuman Reproduction Update, 1998